In contrast, inhibition of HDAC1,2 activity using ACY-957 and/or reducing chromatin-bound EZH2 using DZNep compromised the viability of the chemoresistant DLBCL without reducing global H3K27me3 levels (Figures 3, 4). This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.